HMBD-001 + docetaxel + cetuximab

This is a **combination regimen** composed of three agents: - **HMBD-001:** a clinical-stage, humanized IgG1 monoclonal antibody developed by Hummingbird Bioscience. HMBD-001 targets the HER3 receptor (also known as ERBB3), a member of the EGFR family that drives tumor growth and resistance to cancer therapies through dimerization with HER2 or EGFR. HMBD-001 is uniquely engineered to bind the dimerization interface of HER3, thereby blocking both ligand-dependent and ligand-independent HER3 activation and subsequent MAPK/PI3K signaling, inhibiting tumor growth and resistance[1][5][6]. - **Docetaxel:** a broadly used cytotoxic taxane chemotherapy agent that stabilizes microtubules, preventing their depolymerization and ultimately leading to cell cycle arrest and apoptosis. - **Cetuximab:** a chimeric monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), blocking ligand binding and receptor activation, subsequently inhibiting downstream pro-proliferative and anti-apoptotic pathways in EGFR-expressing tumor cells. The combination of HMBD-001 with chemotherapy and EGFR blockade aims to target overlapping and complementary resistance pathways in solid tumors, particularly those with HER3 activation or mutations. The regimen is being explored in biomarker-selected patient groups, including squamous non-small cell lung cancer (sqNSCLC), tumors with NRG1 fusions, and HER3 mutations[1][2][6].